XOMA 213

Drug Profile

XOMA 213

Alternative Names: LFA102; X 213; XOMA-213

Latest Information Update: 02 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator XOMA
  • Developer Novartis; XOMA
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Prolactin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Prolactinoma
  • Discontinued Breast cancer; Prostate cancer

Most Recent Events

  • 24 Apr 2017 Positive safety and efficacy results from the phase II trial released by XOMA
  • 20 Mar 2017 XOMA 213 is available for licensing as of 16 Mar 2017. http://www.xoma.com/index.htm
  • 24 Feb 2017 XOMA completes a phase II trial for Suppression of lactation in Spain (EudraCT2015-005751-27)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top